Minhua Chu: ESMO Breast Cancer 2026 First-Line Data in a/mTNBC Presented in Fast Oral

Minhua Chu, Managing Partner at Transition Value Partner, shared a post on X:

“ESMO Breast Cancer 2026.

Duality Bio presented a Fast Oral, reporting first‑line data for TROP2 ADC Sacituzumab, Drozuntecan (DB‑1305/BNT325) + PD‑L1×VEGF‑A bispecific pumitamig (BNT327/BMS986545) in a/mTNBC.

Study design:

Phase I/IIa (NCT05438329), dose escalation + expansion
Expansion cohort: untreated unresectable/advanced/metastatic TNBC
Regimen: pumitamig 30 mg/kg Q3W + DB‑1305/BNT325 3.5 mg/kg Q3W
Primary endpoints: ORR, safety
Median age 55.5; 83.3% Chinese patients

Key results (n=30):

uORR 83.3%, cORR 76.7%
DCR 96.7%
Tumor shrinkage in all evaluable patients
95.2% maintained response at 6 months

Safety: Manageable profile.

Grade 3–4 TRAEs: 43.3%
Discontinuation due to TRAEs: 3.3%
Common TRAEs (>40%): mucositis, weight loss, ALT elevated, alopecia (mostly Grade 1–2).”

Minhua Chu